Literature DB >> 3791256

Peak cerebrospinal fluid platinum levels in a patient with ependymoma: evaluation of two different methods of cisplatin administration.

M DeGregorio, B Wilbur, O King, J Wallenberg, S Prewitt, J Phillips, J Wilbur.   

Abstract

Peak CSF and serum platinum levels were examined in a patient with ependymoma after each of four consecutive cisplatin doses of 100 mg/m2 administered by either 30-minute or 3-hour infusion. Both infusion lengths produced similar peak CSF platinum levels within 2 hours after the completion. Ultrafiltrate serum platinum levels correlated with the CSF platinum levels, whereas total plasma platinum did not. No differences in clinical toxicity or response were seen between the two methods of administration. Based on these preliminary results, similar peak CSF platinum concentrations are achieved by 30-minute or 3-hour infusions, and ultrafiltrate serum platinum concentrations can be used to predict these levels.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3791256

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure.

Authors:  A M Spence; M S Berger; R B Livingston; F Ali-Osman; B Griffin
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

Review 2.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study.

Authors:  A Olivi; M Gilbert; K L Duncan; B Corden; D Lenartz; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Platinum-based chemotherapy for recurrent CNS tumours in young patients.

Authors:  E Douek; J E Kingston; J S Malpas; P N Plowman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

5.  Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures.

Authors:  F Doz; M E Berens; D V Dougherty; M L Rosenblum
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

6.  Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.

Authors:  A Boiardi; A Silvani; I Milanesi; M Botturi; G Broggi
Journal:  Ital J Neurol Sci       Date:  1992-12

7.  CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

Authors:  Joerg Dietrich; Ruolan Han; Yin Yang; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2006
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.